Recently, Sierra Medical completed a new round of financing worth hundreds of millions, following nearly RMB 100 million in funding in 2023. This round was led by Boxin Capital, with participation from Aibo Qing Shi, Aier Eye Valley, Hony Capital, and Jiale Capital. Existing shareholder Apricot Capital continued to increase its investment.
It is reported that this round of funding will also accelerate the research and development, clinical trials, and registration of the company's independently developed first phacoemulsification and vitrectomy product line.
Since its establishment in October 2022, Sierra Medical (Suzhou) Co., Ltd. has been an important service provider in the field of medical research, focusing on providing comprehensive solutions for the medical industry. The business of Sierra Medical covers various aspects such as medical research, experimental development, and technical services, promoting the development of the medical field through continuous innovation and professional expertise.
Specifically, Sierra Medical focuses on providing precise, intelligent, and minimally invasive surgical treatment solutions for ophthalmology.
The company's products and projects under development cover vitrectomy accelerators for connecting vitrectomy machines with slower cutting rates; phacoemulsification-vitrectomy integrated machines assist doctors in performing various ophthalmic surgeries, such as cataract surgery and retinal surgery, through cutting, grinding, and tissue processing technologies; disposable ophthalmic medical consumables, including vitrectomy kits and surgical kits, mainly consist of disposable vitrectomy probes, surgical blades, syringes, catheters, guidewires, etc., primarily used for cutting, suturing, injecting, and guiding operations in ophthalmic surgeries.
In 2023, Sierra Medical completed an angel round of financing, with investors including Apricot Capital, Tianhui Capital, and Huatong Capital.